Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.84 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    87,065.70
    +1,131.90 (+1.32%)
     

  • CMC Crypto 200

    1,393.05
    -3.49 (-0.25%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.10 (+2.02%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.26 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

CNW Group
·1 min read

  • Thryv Therapeutics to present virtually at Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28th from 2:15-2:45 p.m. ET.

MONTREAL, Feb. 20, 2024 /CNW/ - Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28th and 29th, 2024. Thryv's virtual presentation will be on February 28th from 2:15-2:45 p.m. ET.

Thryv logo (CNW Group/Thryv Therapeutics Inc.)
Thryv logo (CNW Group/Thryv Therapeutics Inc.)

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

SOURCE Thryv Therapeutics Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2024/20/c6439.html